Last patient treated in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.

January 21 | 2021

According to schedule, 2cureX’s clinical partner University Hospital Vejle has treated the last patient in the TICC1 clinical trial (Clinicaltrials.gov no. NCT03251612) in metastatic colorectal cancer.

2cureX and University Hospital Vejle are in the process of analyzing the clinical data from the trial with expected publication of the results in first quarter of 2021.2cureX will provide update of the clinical study at Redeye’s Fight Cancer 2021 Seminar on 21. January (Fight Cancer 2021 – Jan 21st – Redeye.se).

For more information about 2cureX, please contact:
Ole Thastrup, CEO
E-post: ot@2curex.com
Telefon: +45 22 11 53 99
www.2curex.com

Certified Adviser
Redeye AB
Telefon: +46 8 121 576 90
E-mail: certifiedadviser@redeye.se

————————————————-

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor and the treatment to which the patient is resistant. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany, Sweden and United Kingdom.

IndiTreat® is presently being introduced into the European market.

The aspiration is that IndiTreat® becomes a standard Functional Precision Medicine tool for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: “2CUREX”).